Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Geographic Atrophy Secondary to Age-related Macular Degeneration Clear all
Completed Phase 2 Interventional Results available

A Study of NGM621 in Participants With Geographic Atrophy

NCT04465955
View directory record Official record
Conditions
Geographic Atrophy
Interventions
NGM621, Sham Comparator
Biological · Other
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
55 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
65
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Jul 23, 2026, 4:42 PM EDT
Recruiting Phase 2 Interventional

A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

NCT06659549
View directory record Official record
Conditions
Geographic Atrophy of the Macula
Interventions
GAL-101, Placebo
Drug
Lead sponsor
Galimedix Therapeutics Inc
Industry
Eligibility
55 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Beverly Hills, California • Walnut Creek, California • Hagerstown, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jul 23, 2026, 4:42 PM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT02087085
View directory record Official record
Conditions
Geographic Atrophy, Macular Degeneration
Interventions
400 µg Brimonidine Implant, Sham
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
55 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
23
States / cities
Phoenix, Arizona • La Jolla, California • Mountain View, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Jul 23, 2026, 4:42 PM EDT
Terminated Phase 3 Interventional Results available

A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT02247479
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Lampalizumab, Sham
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
76
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Jul 23, 2026, 4:42 PM EDT
Terminated Phase 3 Interventional Results available

A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT02247531
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Lampalizumab, Sham Comparator
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
975 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
67
States / cities
Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 60 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Jul 23, 2026, 4:42 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy

NCT03777332
View directory record Official record
Conditions
Geographic Atrophy
Interventions
PEGCETACOPLAN (APL-2)
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Bakersfield, California • Beverly Hills, California • Encino, California + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Jul 23, 2026, 4:42 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

NCT05019521
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Danicopan, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
49
States / cities
Phoenix, Arizona • Beverly Hills, California • Encino, California + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Jul 23, 2026, 4:42 PM EDT
Completed Phase 3 Interventional

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD

NCT04770545
View directory record Official record
Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
PEGCETACOPLAN (APL-2)
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
792 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
99
States / cities
Phoenix, Arizona • Bakersfield, California • Campbell, California + 82 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 23, 2026, 4:42 PM EDT
Terminated Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

NCT05893537
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Active Comparator CT1812, Placebo Comparator
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Phoenix, Arizona • Sacramento, California • Walnut Creek, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Jul 23, 2026, 4:42 PM EDT
Recruiting Phase 1Phase 2 Interventional

An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)

NCT07392255
View directory record Official record
Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
CTx001
Genetic
Lead sponsor
Complement Therapeutics
Industry
Eligibility
55 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
4
States / cities
Carmel, Indiana • Reno, Nevada • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 23, 2026, 4:42 PM EDT
Terminated Phase 2 Interventional

A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration

NCT04643886
View directory record Official record
Conditions
Dry Age-related Macular Degeneration, Geographic Atrophy, Macular Degeneration, Retinal Disease, Retinal Degeneration
Interventions
GEM103
Drug
Lead sponsor
Gemini Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
29
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2022 · Synced Jul 23, 2026, 4:42 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT07215234
View directory record Official record
Conditions
Geographic Atrophy
Interventions
SAR446597, Sham Comparator
Drug
Lead sponsor
Sanofi
Industry
Eligibility
60 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
15
States / cities
Peoria, Arizona • Scottsdale, Arizona • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 23, 2026, 4:42 PM EDT
Completed Phase 2 Interventional Results available

Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT01342926
View directory record Official record
Conditions
Atrophy, Geographic
Interventions
GSK933776, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
55 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
40
States / cities
Phoenix, Arizona • Arcadia, California • Irvine, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Jul 23, 2026, 4:42 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

NCT02686658
View directory record Official record
Conditions
Geographic Atrophy, Dry Age-Related Macular Degeneration
Interventions
Avacincaptad Pegol, Sham
Drug · Other
Lead sponsor
IVERIC bio, Inc.
Industry
Eligibility
50 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
55
States / cities
Phoenix, Arizona • Tucson, Arizona • Campbell, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Jul 23, 2026, 4:42 PM EDT
Completed Phase 3 Interventional

Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe

NCT07214740
View directory record Official record
Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
APL-2, Pegcetacoplan
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
5
States / cities
Bakersfield, California • Oxnard, California • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jul 23, 2026, 4:42 PM EDT
Recruiting Phase 2 Interventional

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251

NCT05626114
View directory record Official record
Conditions
Geographic Atrophy
Interventions
OpRegen
Biological
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
15
States / cities
Beverly Hills, California • Sacramento, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 23, 2026, 4:42 PM EDT
Enrolling by invitation Phase 2 Interventional

ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study

NCT05481827
View directory record Official record
Conditions
Age Related Macular Degeneration (AMD)
Interventions
GT005
Genetic
Lead sponsor
Gyroscope Therapeutics Limited
Industry
Eligibility
55 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
22
States / cities
Poway, California • Durango, Colorado • Gainesville, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Jul 23, 2026, 4:42 PM EDT
Terminated No phase listed Observational Results available

Global Atrophie Biomarker Evaluation Study (GABiE)

NCT03935126
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Diagnostics
Diagnostic Test
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
60 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Jul 23, 2026, 4:42 PM EDT
Recruiting No phase listed Observational

A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)

NCT07144137
View directory record Official record
Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
Not listed
Lead sponsor
Complement Therapeutics
Industry
Eligibility
55 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Mountain View, California • Oak Forest, Illinois • Carmel, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 23, 2026, 4:42 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

NCT04005352
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Brolucizumab 6 mg, Aflibercept 2 mg
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
24
States / cities
Phoenix, Arizona • Huntington Beach, California • Loma Linda, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Jul 23, 2026, 4:42 PM EDT
Completed Phase 2 Interventional

GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

NCT03815825
View directory record Official record
Conditions
Macular Degeneration, Geographic Atrophy
Interventions
IONIS-FB-LRx, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
55
States / cities
Phoenix, Arizona • Sun City, Arizona • Beverly Hills, California + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Jul 23, 2026, 4:42 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT01577381
View directory record Official record
Conditions
Age-Related Maculopathy
Interventions
RN6G, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
60 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
83
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Jul 23, 2026, 4:42 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

NCT06722157
View directory record Official record
Conditions
Macular Degeneration, Age-related, Geographic Atrophy
Interventions
BI 771716, Pegcetacoplan, Sham comparator to BI 771716
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
50 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
46
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 23, 2026, 4:42 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Alpha Lipoic Acid in Geographic Atrophy

NCT02613572
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
alpha lipoic acid, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years to 90 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
5
States / cities
Iowa City, Iowa • Teaneck, New Jersey • Eugene, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Jul 23, 2026, 4:42 PM EDT